Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke - Patricia A. Cioe; Garrett S Stang; Danish Azam; Sarah Dugal (Figshare, 2024)

Psilocybin rewires specific mouse cortical networks in lasting ways - Siddhant Pusdekar (The Transmitter, 2024)

Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD - Hancock; Mackenzie; Shambhu Prasad Adhikari; Getz; Nicole (Open Science Framework, 2024)

Alternative therapy for neurological and psychiatric disorders using psilocybin - Henrique Tofoli Vieira Machado; GEOVANA MENDES DE SEIXAS; L. Silva; Mariana Duarte Garcia Brito; Gabriella Assink de Castro (2024)

Attitudes Towards Psilocybin: A General Population’s Opinions on Psilocybin and Psilocybin-Assisted Therapies - Madison M. H. Simounet; Joy Drinnon (Psi Chi Journal of Psychological Research, 2024)

Political Attitudes towards the Legalization of Cannabis and Psilocybin - Emma Cinotti (SSRN Electronic Journal, 2024)

Effects of escitalopram and psilocybin therapy on mesolimbic resting-state functional connectivity in depression - Rebecca Harding; Natalie Ertl; Rabia Zafar; Magnus Wall; Rajkanya Das; David Erritzøe; David Nutt; Robin Carhart-Harris (Neuroscience Applied, 2024)

Long-term effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 model of OCD-like behavior - Michal Brownstien (Neuroscience Applied, 2024)

Uncovering the dynamics of psilocybin in human neural pain circuits with intracranial neural recordings - Tess L. Veuthey; Prasad Shirvalkar (Brain stimulation, 2024)

Therapieresistente Depression: Studie zur Psilocybin-augmentierten Psychotherapie nicht erfolgreich - Friederike Klein (InFo Neurologie + Psychiatrie, 2024)

Supplemental Material for A Critical Evaluation of Psilocybin-Assisted Therapy Protocol Components From Clinical Trial Patients, Facilitators, and Caregivers (Psychotherapy, 2024)

Psilocybin: revealing the enigmas of a revolutionary fungi - RM Moosa-Battey (SA pharmaceutical journal., 2024)

Mushroom bioactives-polysaccharides to psilocybin: a viewpoint on the therapeutic use of mushrooms for consumers and patients for health and neuroplasticity - Charles S. Brennan; Yanyi Huang; Margaret A. Brennan (Translational Food Sciences, 2024)

Moral Considerations and the Experience of Ego Dissolution: Insights from Psilocybin - Azimjon Karimov; Dilshodbek Rasulov (Asian Journal of Ethics in Health and Medicine, 2024)

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2024)

Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms. - Hadley M; Halliday A; Stone JM (Journal of psychoactive drugs, 2024)

Practical considerations in the establishment of psychedelic research programs. - Barnett BS; Vest MF; Delatte MS; King Iv F; Mauney EE; Coulson AJ; Nayak SM; Hendricks PS; Greer GR; Murnane KS (Psychopharmacology, 2024)

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions - Namik Kirlić; Molly Lennard-Jones; Merve Atli; Ekaterina Malievskaia; Nadav Liam Modlin; Stéphanie Knatz Peck; Alice Gaillard; Guy M. Goodwin; Don Koelpin (American Journal of Psychiatry, 2024)

Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research. - O'Donnell KC; Grigsby J; Grob CS (The American journal of psychiatry, 2024)

Psilocybin: From Psychiatric Pariah to Perceived Panacea. - Fonzo GA; Wolfgang AS; Barksdale BR; Krystal JH; Carpenter LL; Kraguljac NV; Grzenda A; McDonald WM; Widge AS; Rodriguez CI; Nemeroff CB. (2024)

Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression. - Ramaekers JG; Reckweg JT; Mason NL. (2024)

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial - Scott T. Aaronson; Andrew van der Vaart; Tammy Miller; Jeffrey LaPratt; Kimberly Swartz; Audrey Shoultz; Margo Lauterbach; Trisha Suppes; Harold A. Sackeïm (American Journal of Psychiatry, 2024)

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration. - Wolfgang AS; McClair VL; Schnurr PP; Holtzheimer PE; Woolley JD; Stauffer CS; Wolf RC; States LJ; Benedek DM; Capaldi VF; Bradley J; Fuller MA; et al. (The American journal of psychiatry, 2024)

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial - Broc A. Pagni; Richard J. Zeifman; Sarah E. Mennenga; Brennan M. Carrithers; Noam Goldway; Snehal Bhatt; Kelley C. O’Donnell; Stephen Ross; Michael P. Bogenschutz (American Journal of Psychiatry, 2024)

Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics. - Manzano-Nunez R; Gomez DA; Toledo-Mendoza C; Perez-Otero M; Matilla IL; Prats C; Perez-Lopez E; Pardo H; Díaz-Pellicer P; De La Torre-Fornell R; Aldea AM. (2024)

Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial - Lewis BR; Hendrick J; Byrne K; Odette M; Wu C; Garland EL. (medRxiv, 2024)

Psychedelic Medicine Exceptionalism. - Cohen IG; Marks M (The American journal of bioethics: AJOB, 2024)

Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms. - Wijesekara T; Xu B. (2024)

Molecular brain imaging of psychedelic action. - Cumming P; Egger K; Knudsen GM (International review of neurobiology, 2024)

Post-traumatic stress disorder in psychedelic research. - Bostoen T; Tap S; Breeksema J; Schoevers R (International review of neurobiology, 2024)

Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease. - Tap S; Bostoen T; Breeksema J; Schoevers R (International review of neurobiology, 2024)

Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes. - Sommer WH; Spanagel R (Current topics in behavioral neurosciences, 2024)

"" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms. - D M Schuman H; Barkova S; Mina R; Deleemans JM; Nguyen T; Carlson LE (Integrative cancer therapies, 2024)

Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts - Farzaneh Norouzkhani; Esmaeel Ghasemi Gojani; Bo Wang; DongPing Li; Salma Shujat; Aadarsh Shrestha; Rocio Rodriguez-Juarez; Olga Kovalchuk; Igor Kovalchuk (Biochemistry and Cell Biology, 2024)

Early psilocybin intervention alleviates behavioral despair and cognitive impairment in stressed Wistar rats - Zitong Wang; Brett Robbins; Ryan Zhuang; Thaísa Meira Sandini; Rebekah van Bruggen; Xin-Min Li; Yanbo Zhang (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2024)

Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021. - Abramsky-Sze S; Marseille E; Matzopoulos R; Morlock R; Lerer L (Frontiers in psychiatry, 2024)

Is there room for ethics of authenticity in psilocybin research? - Stefan Jerotić (Neuroscience Applied, 2024)

Contextual and experiential aspects of the psychedelic experience predicting improvement in subjective wellbeing: results from a Norwegian internet convenience sample. - Tunstad PA; Kvam TM; Uthaug MV; Stewart LH; Andersen KAA; Grønnerød C (Frontiers in pharmacology, 2024)

Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy. - Dwyer J; Johnston RB; O'Callaghan C; Kallianis V; Ross ML (Frontiers in psychiatry, 2024)

PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction. - Marek J; Domek-Gumprecht M; Macionga A; Szafoni S; Więckiewicz G (Frontiers in psychiatry, 2024)

Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns - Katherine Cheung; Maxwell Brodie; Sue-Ling Chang; P. Deschamps; Jean-Sébastien Fallu; Houman Farzin; Johanne Hébert; Jean-François Stephan; Michel Dorval; Yann Joly; for the P3A Study Group (The Journal of Law Medicine & Ethics, 2024)

Home-based psilocybin-assisted therapy for a patient with advanced cancer: A case report - Houman Farzin; Benjamin Koren; Helen Ferrier; Justin J. Sanders; Nicolas Garel (Palliative & Supportive Care, 2024)

The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences. - McHerron D; Barber M; Ham R; Liknaitzky P; Carter A; Gardner J (Therapeutic advances in psychopharmacology, 2024)

Which Psychotherapy Model Should be Used in Psilocybin Treatment for Depression? - Elena Koning; Pedro Starzynski Bacchi; Cristiano Chaves; Fabiano A. Gomes; Elisa Brietzke (Trends in Psychiatry and Psychotherapy, 2024)

Theoretical Description for Psilocin and Coprine Electrochemical Determination in Mushroom Pulp and Biological Liquids over Cobalt (II) Oxyhydroxide-Modified Electrode (Letters in Applied NanoBioScience, 2024)

Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design. - Koning E; Chaves C; Kirkpatrick RH; Brietzke E. (2024)

High-quality draft genomes of ecologically and geographically diverse Psilocybe species - Ian M. Bollinger; Harte Singer; Jordan Jacobs; Marshall Tyler; Kelsey L. Scott; Christopher S. Pauli; Dusty R. Miller; Caine Barlow; Alan Rockefeller; Jason C. Slot; Victor Angel-Mosti (Microbiology Resource Announcements, 2024)

Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner - Miguel Farinha-Ferreira; Catarina Miranda-Lourenço; Chloé Galipeau; Zsolt Lenkei; Ana M. Sebastião (Neuropharmacology, 2024)

Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials. - Swieczkowski D; Kwaśny A; Pruc M; Gaca Z; Szarpak L; Cubała WJ. (2024)

Brain dynamics of classical psychedelics show paradoxical hierarchical flattening with increased complexity - Vohryzek J; Garcia Guzman E; Kringelbach ML; Lopez-Sola E; Timmermann C; Roseman L; Tagliazucchi E; Ruffini G; Carhart-Harris R; Deco G; Sanz Perl Y. (bioRxiv, 2024)

Characterizing psilocybin as an antidepressant for adolescence in male and female rats - García-Cabrerizo R; Beruete-Fresnillo I; García-Fuster MJ. (bioRxiv, 2024)

ALSUntangled #77: Psilocybin. - Bakshi B; Yerraguntla S; Armon C; Barkhaus P; Bertorini T; Bowser R; Breevoort S; Bromberg M; Brown A; Carter GT; Chang V; Crayle J; et al. (2024)

Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma. - Geller J; Whitney E. (2024)

The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample. - Calder AE; Qualls C; Hasler G; Elmiger D; Strassman R. (2024)

A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care. - Miller M; Meyers M; Martin A; Napolitano S; Dorsen C; Penn A; Rosa WE. (2024)

Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise. - Croarkin PE; Sutherland I; Ho MF. (2024)

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression - Guy M. Goodwin; Scott T. Aaronson; Oscar Alvarez; Robin Carhart-Harris; J. Chai-Rees; Megan Croal; Charles DeBattista; Boadie W. Dunlop; David Feifel; David J. Hellerstein; Muhammad Ishrat Husain; John R. Kelly; et al. (Journal of Affective Disorders, 2024)

Psilocybin increases emotional empathy in patients with major depression - Johannes Jungwirth; Robin von Rotz; Isabel Dziobek; Franz X. Vollenweider; Katrin H. Preller (Molecular Psychiatry, 2024)

Psilocybin causes sex, time, and dose dependent alterations in brain signaling pathways - Barnett JH; Todd KT; Benetatos J; Rabichow BE; Gibson KA; Olney KC; Fryer JD. (bioRxiv, 2024)

Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review. - Ferreira AE; Reis-Pina P. (2024)

The Neurobiological Effect of 5-HT2AR Modulation - Gitte Moos Knudsen (ClinicalTrials.gov, 2024)

Short- and long-term reconfiguration of rat prefrontal cortical networks following single doses of psilocybin - Purple RJ; Gupta R; Thomas CW; Golden CT; Froudist-Walsh S; Jones MW. (bioRxiv, 2024)

The safety of psilocybin-assisted psychotherapy: A systematic review. - Freitas RR; Gotsis ES; Gallo AT; Fitzgibbon BM; Bailey NW; Fitzgerald PB. (2024)

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health. - Meyer TD; Ibrahim M; Vale LN; Soares JC. (2024)

Legal and Ethics Concerns of Psilocybin as Medicine. - Schonholz SM; Appel JM; Bursztajn HJ; Nair M; MacIntyre MR. (2024)

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges. - Scala M; Fabbri C; Fusar-Poli P; Di Lorenzo G; Ferrara M; Amerio A; Fusar-Poli L; Pichiecchio A; Asteggiano C; Menchetti M; De Ronchi D; MNESYS - Mood; et al. (2024)

Treatment Expectancies and Psilocybin vs Escitalopram for Depression - Ethan G. Dutcher; Andrew D. Krystal (JAMA Psychiatry, 2024)

Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis. - Marchi M; Farina R; Rachedi K; Laonigro F; Žuljević MF; Pingani L; Ferrari S; Somers M; Boks MPM; Galeazzi GM. (2024)

Quality of reporting on psychological interventions in psychedelic treatments: a systematic review. - Seybert C; Schimmers N; Silva L; Breeksema JJ; Veraart J; Bessa BS; d'Orsi D; Schoevers RA; Oliveira-Maia AJ. (2024)

The many faces of psilocybin-related psychosis: A case series - Yumin Kim; Rachel Bigley; Aubrey DeVinney; Paul S. Nestadt (Psychiatry Research Case Reports, 2024)

Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use - Jonathan Brett; Elizabeth Knock; Kathy Watson; Steven M. Albert; Krista J. Siefried; Jeffrey Guss (Frontiers in Psychiatry, 2024)

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic - Anthony L. Back; Timara K. Freeman-Young; Ladybird Morgan; Tanmeet Sethi; Kelsey K. Baker; Susanna Myers; Bonnie A. McGregor; Kalin Harvey; Marlene Tai; Austin Kollefrath; Brandon J. Thomas; Dennis Sorta; et al. (JAMA Network Open, 2024)

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study - COMPASS Pathways (ClinicalTrials.gov, 2024)

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology. - Shinozuka K; Jerotic K; Mediano P; Zhao AT; Preller KH; Carhart-Harris R; Kringelbach ML. (2024)

Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials. - Terao I; Kodama W. (2024)

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money. - Humphreys K; Todd Korthuis P; Stjepanović D; Hall W. (2024)

Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. - Menon V; Ramamurthy P; Venu S; Andrade C. (2024)

Correction to: A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression by Nayak, et al. Psychedelic Med 2023;1(1):18-26; doi: 10.1089/psymed.2022.0002. (2024)

Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence. - Piercey CJ; Gray B; Sung A; Henry D; Karoly HC. (2024)

Narrative review of psilocybin, an important psychoactive substance with potential peri-anesthetic implications - George Tewfik; Adejuyigbe Adaralegbe; Sangel Gomez; Rania Aziz; Faraz Chaudhry; Daniel Rodriguez-Correa; Dorisanne O. Adaralegbe (Trends in Anaesthesia and Critical Care, 2024)

God hasn’t died, it has merely been encapsulated - Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science - Juan Scuro (Social Compass, 2024)

Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. - Hinkle JT; Graziosi M; Nayak SM; Yaden DB. (2024)

Psychedelics for the Treatment of Obsessive-Compulsive Disorder: Efficacy and Proposed Mechanisms. - Collins HM. (2024)

Psilocybin and hallucinogenic mushrooms. - Fradet M; Kelly CM; Donnelly AJ; Suppes T. (2024)

Psilocybin as a Disease-Modifying Drug-A Salutogenic Approach in Psychiatry. - Spangemacher M; Mertens LJ; Färber LV; Jungaberle A; Jungaberle H; Gründer G. (2024)

Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings - Arman Fard; Allison Cohen (Journal of Student Research, 2024)

Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need. - de Jonge D; van der Meer PB; Kramers C; Schellekens A. (2024)

Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis. - Calder AE; Hase A; Hasler G. (2024)

Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration - Ben-Tal T; Pogodin I; Botvinnik A; Lifschytz T; Heresco-Levy U; Lerer B. (bioRxiv, 2024)

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. - Sabé M; Sulstarova A; Glangetas A; De Pieri M; Mallet L; Curtis L; Richard-Lepouriel H; Penzenstadler L; Seragnoli F; Thorens G; Zullino D; Preller K; et al. (2024)

Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder - Noah D. Gold; Broc A. Pagni; Petros Petridis; Michael P. Bogenschutz (Psychedelic Medicine, 2024)

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder. - Miller CE; Zoladz PR. (2024)

Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates. - Yale University (ClinicalTrials.gov, 2024)

A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder - TRYP Therapeutics (ClinicalTrials.gov, 2024)

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder - Shakila Meshkat; Erica Kaczmarek; Zoe Doyle; Ryan M. Brudner; Fabiano A. Gomes; Marc G. Blainey; Geneva Weiglein; Roger S McIntyre; Rodrigo B. Mansur; Joshua D. Rosenblat (Psychedelic Medicine, 2024)

Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials - Raj Nashikkar; Kavita Mane; Rajendra Patil (International Journal for Research in Applied Science and Engineering Technology, 2024)

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals - Erin Y. Wang; David S. Mathai; Natalie Gukasyan; Sandeep M. Nayak; Albert Garcia-Romeu (Scientific Reports, 2024)

Associations between psychedelic use and cannabis use disorder in a nationally representative sample. - Zech JM; Yaden DB; Jones GM. (2024)

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. - Reid MJ; Kettner H; Blanken TF; Weiss B; Carhart-Harris R. (2024)

The Effect of Psilocybe cubensis on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress - Reza Ghaffarzadegan; Mokhtar Karimi; Behnaz Hedayatjoo; Hamidreza Behnoud; Eghbal Jasemi; Mahsa Mohammadi; Samira Roustaei; Ali Razmi; Salar Vaseghi (Journal of Psychoactive Drugs, 2024)

PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout - University of Utah (ClinicalTrials.gov, 2024)

Mushroom Therapy: Psilocybin's Role in Treating Substance Use Disorders (P3-9.018). (Neurology, 2024)

Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT2A receptor activation and psychedelic-like activity. - Zhang M; Yang Y; Yang Z; Wen X; Zhang C; Xiao P; Wang Y; Sun J; Wang H; Wang X. (2024)

Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment. - Kargbo RB. (2024)

Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications. - Kargbo RB. (2024)

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial - Jiwon Lee; Kaylyssa Philip; Duminda N. Wijeysundera; Hance Clarke; Cheryl Pritlove; Joel Katz; Paul Ritvo; Akash Goel; Muhammad Ishrat Husain; Karim S. Ladha (Canadian Journal of Pain, 2024)

Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help - Stéphanie Knatz Peck; Hannah M. Fisher; Jessie Kim; Samantha Shao; Julie Trim; Walter H. Kaye (Psychedelics., 2024)

Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms - Hodge A; Forsyth A; Noorani T; Muthukumaraswamy S; Rolleston A; McHugh P. (PsyArXiv, 2024)

Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits - Pasquini L; Vohryzek J; Escrichs A; Sanz Perl Y; Ponce-Alvarez A; Idesis S; Girn M; Roseman L; Mitchell JM; Gazzaley A; Kringelbach M; Nutt DJ; et al. (bioRxiv, 2024)

Amid magic and menace: psychiatrists’ attitudes to psilocybin therapy - Andrew Gribben; T. R. JUN. BURKE; Colm Harrington; Amanda Husein; Kevin S. Murnane; Peter S. Hendricks; Katy Tobin; Jo-Hanna Ivers; Guillaume Thuery; Andrew Harkin; John R. Kelly (Irish Journal of Psychological Medicine, 2024)

PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study) - Imperial College London (ClinicalTrials.gov, 2024)

Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies. - Barstowe A; Kajonius PJ. (2024)

Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial - Link Swanson; Sophia Jungers; Ranji Varghese; Kathryn R. Cullen; Michael D. Evans; Jessica L. Nielson; Michael-Paul Schallmo (Journal of Vision, 2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. - Valdez T; Patel V; Senesombath N; Hatahet-Donovan Z; Hornick M. (2024)

Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions - Marcel Nogueira; Solimary García-Hernández; Gleicy Sotéro Roberto; Leonardo Zanella Marques (International journal of medicinal mushrooms, 2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial - Aday JS; McAfee J; Conroy DA; Hosanagar A; Tarnal V; Weston C; Scott K; Horowitz D; Harte SE; Pouyan N; Glynos NG; Baker AK; et al. (PsyArXiv, 2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial (PsyArXiv, 2024)

Pyramidal cell types and 5-HT2A receptors are essential for psilocybin’s lasting drug action - Shao L; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu R; Woodburn SC; Bilash OM; Kim H; et al. (bioRxiv, 2024)

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: case report and thematic analysis of one participant's experience - Mourad Wahba; Caroline Hayes; Maartje Kletter; R. Hamish McAllister-Williams (BJPsych Open, 2024)

Psilocybin alters the circulating metabolomic profile in both non-clinical and clinical models - Emese Prandovszky O’Donnell; Zachary A. Cordner; Hua Liu; Shuojia Yang; Lindsey Macias; Kellie L. Tamashiro; Frederick S. Barrett; Robert H. Yolken (Brain Behavior and Immunity, 2024)

Psilocybin-unterstützte Psychotherapie reduziert Ängste und Depressionen - Lamia Özgör (InFo Hämatologie + Onkologie, 2024)

Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus - D Silva; Antônio Carlos Pereira de Menezes Filho; Aurélio Ferreira Melo; Porshia Sharma; Tullyo Henrique Lima Machado; Vanêcia Oliveira Cunha Machado; Matheus Vinícius Abadia Ventura (Brazilian Journal of Science, 2024)

Optimized psilocybin production in tryptophan catabolism-repressed fungi - Slavica Janevska; Sophie Weiser; Ying Huang; Jun Lin; Sandra Hoefgen; Katarina Jojić; Amelia E. Barber; Tim Schäfer; Janis Fricke; Dirk Hoffmeister; Lars Regestein; Vito Valiante; et al. (Microbial Biotechnology, 2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts - Luoma JB; Wilson-Poe A; Pertl K; Hoffman K; Bazinet A; Stauffer C; McCarty D; Korthuis P. (PsyArXiv, 2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts (PsyArXiv, 2024)

Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials - Sepehr Aghajanian; Arman Shafiee; Samira Parvizi Omran; Aida Rezaei Nejad; Kyana Jafarabady; Omid Kohandel Gargari; Shahryar Rajai Firouzabadi; Ida Mohammadi; Touran Bahrami Babaheidari; Mahmood Bakhtiyari (Journal of Psychopharmacology, 2024)

A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study - Filament Health Corp. (ClinicalTrials.gov, 2024)

A narrative exploration of psilocybin's potential in mental health. - Min H; Park SY; Park J; Na S; Lee HS; Kim T; Ham J; Park YT. (2024)

“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin - Pamela Kryskow; Paul Stamets; Joseph La Torre; Kathy Sattler; Vivian W. L. Tsang; Monnica T. Williams (Journal of Psychedelic Studies, 2024)

Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner - Kennedy R. Wiens; Noah A. H. Brooks; Ishvin Riar; Bridget K. Greuel; Ivan A. Lindhout; Andis Klegeris (Molecules, 2024)

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms - Imperial College London (ClinicalTrials.gov, 2024)

Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (bioRxiv, 2024)

Expert recommendations for Germany's integration of psychedelic-assisted therapy. - Perez Rosal SR; La Torre JT; Birnkammer S; Chernoloz O; Williams MT; Faber SC. (2024)

Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis - Kai Rogge; Tobias Wagner; Dirk Hoffmeister; Bernhard Rupp; Sebastiaan Werten (FEBS Letters, 2024)

Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration - Mott; Sarah E.; Clyde W. Hodge; Jessica L. Hoffman; Maria Echeveste Sanchez; Christian S. Rollison; Margaret W. High; Devin P. Effinger; Melissa A. Herman; Sarah N. Magee; Daniel Toedt; Sema G. Quadir (UNC Libraries, 2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics - Majic T; Schmidt TT; Gröticke A; Gasser P; Richards WA; Riemer TG; Evens R. (PsyArXiv, 2024)

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin - Mallaroni P; Singleton P; Mason NL; Satterthwaite TD; Ramaekers JG. (bioRxiv, 2024)

Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study - Grant Jones; Matthew X. Lowe; Sandeep M. Nayak; Nathan D. Sepeda; Hannes Kettner; Robin Carhart-Harris; Heather Jackson; Albert Garcia-Romeu (Journal of Affective Disorders, 2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics (PsyArXiv, 2024)

The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice - Fleury S; Nautiyal KM. (bioRxiv, 2024)

Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study - Stefanie Enriquez-Geppert; Jaroslav Krc; Fiachra O'Higgins; Morten Peter Lietz (Philosophical Transactions of the Royal Society B Biological Sciences, 2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. - Hooper J; Gyongyosi E; Hutchison K; Mueller R. (PsyArXiv, 2024)

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study - University Health Network; Toronto (ClinicalTrials.gov, 2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. (PsyArXiv, 2024)

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task. - Olami A; Peled-Avron L. (2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders - Valdez T; Patel V; Senesombath D; Hatahet-Donovan Z; Hornick MG. (Preprints.org, 2024)

Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases. - Szpręgiel I; Bysiek A. (2024)

The Second Methylation in Psilocybin Biosynthesis Is Enabled by a Hydrogen Bonding Network Extending into the Secondary Sphere Surrounding the Methyltransferase Active Site - Jesse Hudspeth; Kai Rogge; Tobias Wagner; Maximilian Müll; Dirk Hoffmeister; Bernhard Rupp; Sebastiaan Werten (ChemBioChem, 2024)

Expanding the Therapeutic Horizons of Psilocybin in Mental Health. - Kargbo RB. (2024)

Psilocybin-assisted psychotherapy as an ‘anti-distressant’ with multidimensional properties - Danica E. Johnson; Joshua D. Rosenblat (Nature Mental Health, 2024)

Human brain changes after first psilocybin use - Lyons T; Spriggs M; Kerkelä L; Rosas F; Roseman L; Mediano P; Timmermann C; Oestreich L; Pagni B; Zeifman R; Hampshire A; Trender W; et al. (bioRxiv, 2024)

A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics - Barnett BS. (medRxiv, 2024)

Characterization and Identification of an Antimicrobial Compound Psilocybin from Psychedelic Mushroom. - Karthiyayini B; Kalyani NN; Gowdhami B; Muthuselvam M; Dharumadurai D. (2024)

Snapshot of 5-HT2A receptor activation in the mouse brain via IP1 detection - de la Fuente Revenga M; González-Maeso J. (bioRxiv, 2024)

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression - Lindsey Marwood; Megan Croal; Sunil Mistry; Hollie Simmons; Joyce Tsai; Matthew B. Young; Guy M. Goodwin (Journal of Psychiatric Research, 2024)

The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment - Hannah Douglass (Open MIND, 2024)

Does psilocybin reduce symptoms of depression in adults with major depressive disorder or life-threatening cancer? - Morgan Justin; Kerry Watrin (Evidence-Based Practice, 2024)

Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study - James Rucker; Matthew Butler; Sadie Hambleton; Catherine Bird; Mathieu Seynaeve; Sanjay Cheema; Kete Campbell-Coker; Carolina Maggio; Fiona Dunbar; Giorgio Lambru; Manjit Matharu (Headache The Journal of Head and Face Pain, 2024)

A psilocybin haven: the use of comparison to legitimate transgression at a psychedelic retreat - Jesper Dunell (Drugs Education Prevention and Policy, 2024)

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2024)

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. - Imperio CG; Levin FR; Martinez D. (2024)

The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis. - Li JR; Chiang KT; Kao YC; Yu CL; Yang FC; Liang CS; Hsu TW. (2024)

Neuroprotective effects of psilocybin in a rat model of stroke - Seong-Jin Yu; Kuo-Jen Wu; Yu-Syuan Wang; Eun-Kyung Bae; Fabio Chianelli; Nicholas C. Bambakidis; Yun Wang (BMC Neuroscience, 2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol - Pincombe J; Williams M; Carruthers S; Rossell S. (PsyArXiv, 2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol (PsyArXiv, 2024)

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer - Petros Petridis; Jack Grinband; Gabrielle Agin-Liebes; Connor J. Kinslow; Richard J. Zeifman; Michael P. Bogenschutz; Roland R. Griffiths; Stephen Ross (Nature Mental Health, 2024)

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome - Jack D. C. Dahan; David Dadiomov; Tijmen Bostoen; Albert Dahan (npj Mental Health Research, 2024)

Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex - Victorita E. Ivan; David P. Tomàs-Cuesta; Ingrid M. Esteves; Artur Luczak; Majid H. Mohajerani; Bruce L. McNaughton; Aaron J. Gruber (European Journal of Neuroscience, 2024)

Exploring the biocatalysis of psilocybin and other tryptamines: Enzymatic pathways, synthetic strategies, and industrial implications. - Junges LH; Müller-Santos M. (2024)

Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. - Choi C; Johnson DE; Chen-Li D; Rosenblat J. (2024)

Does psilocybin really provide long-term relief from depression, as new study suggests? - Johan Lundberg; Guusje Haver (2024)

PR012/#955 Psilocybin assisted psychotherapy for patients with ovarian caner: a subset analysis of a randomized, double-blind, placebo-controlled, phase II clinical trial - Daniel Spinosa; Stacy M. Fischer; Richard J. Zeifman; Carolyn Lefkowits; Petros Petridis; Stephen Ross (International Journal of Gynecological Cancer, 2024)

From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice. - Schenberg EE. (PsyArXiv, 2024)

Artificial intelligence and psychedelic medicine. - Sarris J; Halman A; Urokohara A; Lehrner M; Perkins D (Annals of the New York Academy of Sciences, 2024)

What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study - Marianne Masse-Grenier; Sue-Ling Chang; Ariane Bélanger; Jean-François Stephan; Johanne Hébert; P. Deschamps; Louis Plourde; François Provost; Houman Farzin; Jean-Sébastien Fallu; Michel Dorval (Palliative & Supportive Care, 2024)

Impact of psilocybin on cognitive function: A systematic review. - Meshkat S; Tello-Gerez TJ; Gholaminezhad F; Dunkley BT; Reichelt AC; Erritzoe D; Vermetten E; Zhang Y; Greenshaw A; Burback L; Winkler O; Jetly R; et al. (2024)

From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice. (PsyArXiv, 2024)

Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex - Lane CP; Tarka VM; Valentin O; Lehmann A; Hamel E; de Villers-Sidani E. (bioRxiv, 2024)

Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats - Elizabeth L. Fisher; Ryan Smith; Kyna-Anne Conn; Andrew W. Corcoran; Laura K Milton; Jakob Hohwy; Claire J. Foldi (Translational Psychiatry, 2024)

Beyond the numbers: reimagining healing with psychedelics for eating disorders. - Lafrance A; Spriggs MJ; Gukasyan N; Peck SK (Journal of eating disorders, 2024)

What should constitute a control condition in psychedelic drug trials? - Colloca L; Fava M. (2024)

Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy. - Halman A; Conyers R; Moore C; Khatri D; Sarris J; Perkins D. (2024)

Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy. - Ordovich-Clarkson RD; Jabbour M; Pelayo DA; Lara D; La Croix S; Mumman M; Stukas S; Anderson R; Meraz D; Bangura A; Anderson B; Bamrud L; et al. (2024)

The Action on Psilocybin in Neural Plasticity, Brain Reorganization and Cognitive Enhancement - Carlos Henrique Marchiori; Marco Vinícios de Oliveira Santana; Klebert de Paula Malheiros (Middle East Research Journal of Biological Sciences, 2024)

The Effects of Psilocybin on Shared Experience in Film Processing - Western University; Canada (ClinicalTrials.gov, 2024)

Impact of Protonation Sites on Collision-Induced Dissociation-MS/MS Using CIDMD Quantum Chemistry Modeling. - Lee J; Tantillo DJ; Wang LP; Fiehn O. (2024)

Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study - Sara Ellis; Catherine Bostian; Wendy Feng; E. Grace Fischer; Garrett Schwartz; Katherine Eisen; Melanie Lean; Elizabeth Conlan; Michael J. Ostacher; Scott T. Aaronson; Trisha Suppes (Journal of Affective Disorders, 2024)

Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative study - Aleš Oblak; Liam Korošec Hudnik; Anja Levačić; Kristian Elersič; Peter Pregelj; Jurij Bon (Philosophical Psychology, 2024)

Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity - Allohverdi S; Soltanzadeh M; Schmidt A; Charlton C; Hauke D; Karvelis P; Vollenweider F; Diaconescu A. (Research Square, 2024)

An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder - University of California; San Francisco (ClinicalTrials.gov, 2024)

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction. - Vamvakopoulou IA; Nutt DJ. (2024)

Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice - Abe Y; Sugiura Y; Maeda R; Taira S; Yoshida K; Ibi D; Moritoh S; Hashimoto K; Yagishita S; Tanaka KF. (bioRxiv, 2024)

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder - Xi Zhu; Chen Zhang; David J. Hellerstein; Jamie D. Feusner; Michael G. Wheaton; Gloria J. Gomez; Franklin R. Schneier (Psychedelics., 2024)

Psilocybin legalization in the United States and psychological reactance: A test of evidence uncertainty, controlling language, and an ambiguous call to action. - Brian L. Quick; Ethan Morrow; Sam R. Wilson; Minhey Chung; Daniel E. Hartman; Brenda Koester (Motivation Science, 2024)

Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment - Lazar M; Brownstien M; Botvinnik A; Shevakh C; Shahar O; Lifschytz T; Lerer B. (bioRxiv, 2024)

Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. - Li LJ; Mo Y; Shi ZM; Huang XB; Ning YP; Wu HW; Yang XH; Zheng W. (2024)